According to vaccine-maker Pfizer, in case there was a "vaccine-escape" variant, the company expects to be able to develop and produce a new tailor-made vaccine against that variant within about 100 days.
Market Reaction
The comments from Pfizer have offered little solace to a still overall very risk-off market. 100 days for a vaccine is good, but then nations would have to roll the vaccine out, which as seen in 2021, takes many months.
A vaccine-resistant variant, if that is what the new South African variant turns out to be, could still deliver a significant blow to the global economic outlook over the next six months if nations significantly tighten lockdowns and travel restrictions and consumers begin to fear the virus again.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD consolidates below 1.0450 after weak EU data
EUR/USD keeps its range below 1.0450 after softer Eurozone PPI and Sentix data. The US dollar struggles to find its feet amid a better risk tone and light trading conditions. Recession fears and Fed-ECB policy contrast continue to remain in play.
GBP/USD defends bids above 1.2100 amid fresh UK political jitters
GBP/USD is defending minor bids above 1.2100, as investors weigh another attempt to oust UK PM Johnson amid looming Brexit woes. The US dollar eases in a mildly positive risk environment. Thinner liquidity conditions will prevail amid the US holiday.
Gold eyes $1,798 and $1,794 as next downside targets
Gold Price returns to the red zone despite weaker US Treasury yields. Markets remain cautious ahead of the Fed Minutes and an impending death cross. XAUUSD could resume sell-off below $1,800 amid light trading conditions.
Cryptos at risk following KuCoin insolvency rumors
Bitcoin price has been ranging since June 18, but rumors of insolvency have been spreading on multiple popular platforms in the industry. KuCoin is at the center of bankruptcy rumors.
FXStreet Premium users exceed expectations
_XtraSmall.png)
Tap into our 20 years Forex trading experience and get ahead of the markets. Maximize our actionable content, be part of our community, and chat with our experts. Join FXStreet Premium today!